Your search for apixaban returned 51 results

A recent report published in the New England Journal of Medicine describes the case of a patient with persistent skin discoloration associated with the use of the antiarrhythmic agent amiodarone. The 81-year-old man presented to the emergency department after a fall, which was eventually attributed to orthostatic hypotension. His medical history included atrial fibrillation and…

Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.

Bristol-Myers Squibb and Pfizer announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy.

Asundexian is an investigational oral Factor XIa inhibitor.

Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.

Bristol-Myers Squibb and Pfizer announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial according to patient age in patients with nonvalvular atrial fibrillation (NVAF).

According to the findings of a recent study, attorney advertisements appear to influence patients’ decisions on modifying or discontinuing their direct oral anticoagulant (DOAC) medication prior to seeking medical advice.

A list of medications routinely prescribed in primary care practice that should be used cautiously or avoided in patients with chronic kidney disease (CKD) was compiled in a recently published study in the Annals of Pharmacotherapy.

The main outcomes and measures were intraocular bleeding events and associated risk ratio for NOACs, compared with warfarin.

Bristol-Myers Squibb and Pfizer announced that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with Eliquis (apixaban) compared to warfarin (Coumadin; Bristol-Myers Squibb) in the Phase 3 ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation; these were results from a subanalysis from the study.